Banco Bilbao Vizcaya Argentaria S.A. Has $44.90 Million Stock Holdings in Pfizer Inc. $PFE

Banco Bilbao Vizcaya Argentaria S.A. raised its position in Pfizer Inc. (NYSE:PFE) by 1.8% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,767,812 shares of the biopharmaceutical company’s stock after acquiring an additional 30,478 shares during the period. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in Pfizer were worth $44,895,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the company. Grey Fox Wealth Advisors LLC bought a new stake in shares of Pfizer during the third quarter valued at approximately $29,000. Howard Hughes Medical Institute acquired a new position in shares of Pfizer in the second quarter valued at $30,000. True Wealth Design LLC lifted its position in Pfizer by 302.5% in the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 974 shares during the period. Darwin Wealth Management LLC acquired a new stake in Pfizer during the second quarter worth $32,000. Finally, Evelyn Partners Asset Management Ltd acquired a new stake in Pfizer during the second quarter worth $33,000. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

PFE has been the subject of a number of recent research reports. BMO Capital Markets restated an “outperform” rating and issued a $30.00 price objective on shares of Pfizer in a research note on Monday, March 9th. Citigroup initiated coverage on shares of Pfizer in a research report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 target price on the stock. Wolfe Research set a $24.00 target price on shares of Pfizer and gave the company an “underperform” rating in a research note on Wednesday, December 17th. Morgan Stanley dropped their price target on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a research report on Friday, December 12th. Finally, Barclays began coverage on shares of Pfizer in a research note on Thursday, February 19th. They set an “underweight” rating and a $25.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, fourteen have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and an average target price of $28.05.

Pfizer Price Performance

NYSE:PFE opened at $26.60 on Friday. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. The firm has a market cap of $151.23 billion, a PE ratio of 19.56 and a beta of 0.47. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.94. The company’s 50-day moving average price is $26.50 and its two-hundred day moving average price is $25.52.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. The company had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. Pfizer’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.63 earnings per share. On average, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: China approves Pfizer’s GLP‑1 weight‑management drug Xianweiying, opening a large, fast‑growing market and adding a new commercial revenue stream in 2026+ — potential upside to international sales. Pfizer’s Weight Management Drug Wins China Approval
• Positive Sentiment: Promising Phase 2 results for tilrekimig (trispecific antibody) in atopic dermatitis reinforce Pfizer’s immunology pipeline; if confirmed in later trials, this could be a material franchise expansion. How Tilrekimig’s Trispecific Eczema Data At Pfizer (PFE) Has Changed Its Investment Story
• Positive Sentiment: Pfizer advanced an early‑stage oncology candidate (PF‑07994525), expanding its cancer pipeline and showing continued R&D momentum in higher‑value therapeutic areas. Pfizer Advances Early-Stage Cancer Candidate PF-07994525
• Positive Sentiment: Scotiabank reaffirmed a Buy rating on PFE, providing analyst support that can help stabilize sentiment among institutional holders. Scotiabank Sticks to Their Buy Rating for Pfizer (PFE)
• Neutral Sentiment: Market research reports highlight long‑acting growth‑hormone (Ngenla/somatrogon) market expansion and regional opportunities (Asia‑Pacific growth), useful for medium‑term planning but not immediate earnings. Ngenla (somatrogon: Pfizer) Market Research Report 2026
• Neutral Sentiment: Separate market research on Tivdak (tisotumab vedotin) underscores oncology demand and biomarker opportunities; supportive for long‑term growth but not an immediate catalyst. Tivdak (Genmab, Pfizer: tisotumab vedotin-tftv) Market Research Report 2026
• Neutral Sentiment: Industry reports on AI in life sciences list Pfizer among firms accelerating AI‑driven drug discovery; this supports long‑run efficiency gains but faces regulatory/cost adoption timelines. AI in Life Sciences Market, 2026-2040
• Negative Sentiment: Persistent headwinds — post‑COVID revenue normalization and drug‑pricing pressure — continue to weigh on sentiment; commentary urging buy due to a high dividend yield reflects a lower share‑price base rather than improving top‑line momentum. 1 Magnificent Dividend Stock Down 57% to Buy and Hold Forever
• Negative Sentiment: Short‑term sell pressure: outlets and data summaries note PFE has dipped more than the broader market in recent sessions, suggesting positioning/rotation risk for today’s weakness. Pfizer (PFE) Sees a More Significant Dip Than Broader Market

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.